Key facts
- This page summarizes Eric Francois's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2021, 21:41.
Eric Francois - 01 Jul 2021 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)
- Reporting relationship
- Director
- Issuer ticker
- CRVO
- Reported as of
- 01 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2021, 21:41:36 UTC
- Prior SEC filing
- 15 Oct 2021
- Next SEC filing
- 21 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Elder, as attorney-in-fact for the Reporting Person
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Francois filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 06 Jul 2021.
Change
- Previous filing in this sequence was filed on 15 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DFFN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +83,300
- Change %
- Price
- $0.000000
- Shares after
- 83,300
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,300
- Exercise price
- $0.7200
- Footnotes
- F1
DFFN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +83,300
- Change %
- Price
- $0.000000
- Shares after
- 83,300
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,300
- Exercise price
- $0.7200
- Footnotes
- F2
DFFN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +69,400
- Change %
- Price
- $0.000000
- Shares after
- 69,400
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,400
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021.
Footnote F2
The shares underlying the options will vest in 18 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over an 18-month period beginning July 1, 2021.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F4
The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023.